A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

Status:
Not yet recruiting

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

To learn if adding pembrolizumab to mitotane can help to control ACC. The safety of this drug combination will also be studied.

Phase 2

M.D. Anderson Cancer Center

Mitotane
Pembrolizumab